title: Paclitaxel-induced lung injury and its amelioration by parecoxib sodium.
abstract: To investigate the mechanism of paclitaxel-induced lung injury and its amelioration by parecoxib sodium. In this study, rats were randomly divided into: the control group (Con); the paclitaxel chemotherapy group (Pac); the paclitaxel+ parecoxib sodium intervention group (Pac + Pare); and the parecoxib sodium group (Pare). We observed changes in alveolar ventilation function, alveolar-capillary membrane permeability, lung tissue pathology and measured the levels of inflammatory cytokines and cyclooxygenase-2 (Cox-2) in lung tissue, the expression of tight junction proteins (Zo-1 and Claudin-4). Compared with the Con group, the lung tissue of the Pac group showed significantly increased expression of Cox-2 protein (p < 0.01), significant lung tissue inflammatory changes, significantly increased expression of inflammatory cytokines, decreased expression of Zo-1 and Claudin-4 proteins (p < 0.01), increased alveolar-capillary membrane permeability (p < 0.01), and reduced ventilation function (p < 0.01). Notably, in Pac + Pare group, intraperitoneal injection of parecoxib sodium led to decreased Cox-2 and ICAM-1 levels and reduced inflammatory responses, the recovered expression of Zo-1 and Claudin-4, reduced level of indicators reflecting the high permeability state, and close-to-normal levels of ventilation function. Intervention by the Cox-2-specific inhibitor parecoxib sodium can block this damage.
authors.affiliation: 1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, PR China. [2] Pain management of the first affiliated hospital of Zheng-Zhou University, Zhengzhou, Henan, PR China.
authors.forename: Wen-jie
authors.initials: WJ
authors.lastname: Liu
authors.affiliation: 1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, PR China. [2] Department of Anaesthesia, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.
authors.forename: Zhong-jian
authors.initials: ZJ
authors.lastname: Zhong
authors.affiliation: 1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, PR China. [2] Department of Anaesthesia, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.
authors.forename: Long-hui
authors.initials: LH
authors.lastname: Cao
authors.affiliation: 1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, PR China. [2] Department of Anaesthesia, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.
authors.forename: Hui-ting
authors.initials: HT
authors.lastname: Li
authors.affiliation: 1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, PR China. [2] Department of Anaesthesia, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.
authors.forename: Tian-hua
authors.initials: TH
authors.lastname: Zhang
authors.affiliation: 1] Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, PR China. [2] Department of Anaesthesia, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China. [3] Department of Blood transfusion, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, PR China.
authors.forename: Wen-qian
authors.initials: WQ
authors.lastname: Lin
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000633:toxicity*; D001784:Blood Gas Analysis; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D062506:Claudin-4 / Q000378:metabolism; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology*; D016207:Cytokines / Q000032:analysis; D005260:Female; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D007555:Isoxazoles / Q000494:pharmacology*; D007962:Leukocytes / Q000166:cytology / Q000378:metabolism; D008168:Lung / Q000378:metabolism / Q000473:pathology; D055370:Lung Injury / Q000209:etiology* / Q000378:metabolism / Q000473:pathology; D017239:Paclitaxel / Q000633:toxicity*; D010539:Permeability / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D062826:Zonula Occludens-1 Protein / Q000378:metabolism
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D062506:Claudin-4; D052246:Cyclooxygenase 2 Inhibitors; D016207:Cytokines; D007555:Isoxazoles; C569044:Tjp1 protein, rat; D062826:Zonula Occludens-1 Protein; D018799:Intercellular Adhesion Molecule-1; C409945:parecoxib; D051546:Cyclooxygenase 2; D017239:Paclitaxel